Skip to main content
. 2022 Apr 27;12:874731. doi: 10.3389/fonc.2022.874731

Figure 6.

Figure 6

Potential implications for immunotherapy and TME landscape estimation between the high- and low-LMI groups. (A) Results of GSVA in TCGA-BRCA cohort to delineate the enriched pathways. (B) Differences of ESTIMATE score, immune score, stromal score, and tumor purity. (C) Expression levels of immune checkpoints. (D) Violin plots to display the proportions of 22 immune infiltrating cells in total BC patients. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.